logo

PYPD

PolyPidยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

PYPD Profile

Polypid Ltd.

A biopharmaceutical company developing and commercializing extended-release, locally administered therapies

Pharmaceutical
02/28/2008
06/26/2020
NASDAQ Stock Exchange
58
12-31
Common stock
18 Hasivim Street, Petach Tikva 4959376, Israel
--
PolyPid Ltd., incorporated under the laws of Israel, commenced operations on February 28, 2008. The Company is a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, topically administered and sustained-release therapies using proprietary PLEX technology. The company's product candidates are designed to address diseases with high unmet medical need by pairing PLEX technology with FDA-approved drugs or innovative drug candidates to achieve new therapeutic effects.